Synergistic ADPR Combinations for Enhanced Therapeutic Outcomes

Publication ID: 24-11857561_0003_PTD

Published: October 28, 2025

Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Synergistic ADPR Combinations for Enhanced Therapeutic Outcomes,” Published Technical Disclosure No. 24-11857561_0003_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857561_0003_PTD

This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,561.

Summary of the Inventive Concept

The present inventive concept integrates 5′-adenosine diphosphate ribose (ADPR) compositions with distinct technologies like AI, IoT, blockchain, and novel materials to create a more powerful system for treating adenovirus-related diseases, eye disorders, cancer, and other conditions.

Background and Problem Solved

The original patent disclosed the use of ADPR compositions for treating various diseases. However, the original patent's limitations include the lack of personalized dosing, limited monitoring capabilities, and inadequate data tracking. The new inventive concept addresses these limitations by synergistically combining ADPR compositions with cutting-edge technologies to enhance therapeutic outcomes.

Detailed Description of the Inventive Concept

The new inventive concept comprises ADPR compositions integrated with AI modules for personalized dosing, IoT sensors for real-time monitoring, blockchain-based platforms for secure data tracking, and novel materials for targeted delivery. Claim 1 discloses a system for treating adenovirus-related diseases using AI-assisted ADPR compositions. Claim 2 describes a method for preventing eye disorders using IoT-enabled ADPR compositions. Claim 3 presents a blockchain-based platform for tracking ADPR administration. Claim 4 introduces a novel material for targeted ADPR delivery. Claim 5 outlines a system for managing cancer treatment using machine learning-assisted ADPR compositions.

Novelty and Inventive Step

The new inventive concept's novelty lies in the synergistic combination of ADPR compositions with distinct technologies, which provides a non-obvious solution to the limitations of the original patent. The inventive step is the integration of these technologies to create a more powerful system for enhanced therapeutic outcomes.

Alternative Embodiments and Variations

Alternative embodiments include using different AI algorithms, IoT sensors, or blockchain platforms. Variations may include integrating ADPR compositions with other technologies like robotics, nanotechnology, or gene editing.

Potential Commercial Applications and Market

The new inventive concept has significant commercial potential in the pharmaceutical, healthcare, and biotechnology industries. Target markets include hospitals, clinics, and research institutions focused on adenovirus-related diseases, eye disorders, cancer, and other conditions.

Section 103 Obviousness Analysis (PHOSITA)

▼

Field of Art

Pharmaceutical biotechnology, specifically focused on ADPR compositions for therapeutic interventions in infectious diseases, eye disorders, and cancer treatment

Person of Ordinary Skill (PHOSITA) Profile

A skilled practitioner with advanced degrees in pharmaceutical sciences, biotechnology, or related fields, possessing expertise in drug delivery systems, medical technologies, and computational healthcare solutions

Obviousness Rationale

A PHOSITA would recognize that integrating digital technologies with pharmaceutical compositions represents a predictable evolution of medical treatment methodologies. The source patent's broad claims for ADPR compositions inherently suggest opportunities for technological enhancement and personalized medicine approaches. The proposed variations represent logical extensions of existing pharmaceutical and digital health technologies that would be apparent to a skilled practitioner seeking to optimize therapeutic interventions.

Obvious Combinations & Variations

Source Patent Element

Pharmaceutical composition for treating microorganism infections and disorders

PTD Variation

AI-assisted dosing module for ADPR compositions with real-time patient response monitoring

Obviousness Reasoning

Personalized medicine and adaptive dosing are well-established techniques in pharmaceutical research, representing a predictable application of machine learning to existing therapeutic frameworks

Source Patent Element

Topical administration methods for ADPR compositions

PTD Variation

IoT sensors for tracking and adjusting treatment protocols in eye and respiratory disorders

Obviousness Reasoning

Remote patient monitoring and adaptive treatment protocols are known techniques in medical technology, representing a straightforward technological enhancement

Source Patent Element

Pharmaceutical compositions with various ADPR formulations

PTD Variation

Blockchain-based tracking platform for secure administration and efficacy monitoring

Obviousness Reasoning

Secure medical record management and treatment tracking are standard objectives in healthcare technology, representing an obvious technological integration

Source Patent Element

Pharmaceutical compositions for treating various disorders

PTD Variation

Targeted delivery using biodegradable nanoparticle polymer matrices

Obviousness Reasoning

Advanced drug delivery systems using nanoparticle technologies are well-known in pharmaceutical research, representing a predictable optimization of existing compositional approaches

Source Patent Element

Compositions for managing infectious and inflammatory conditions

PTD Variation

Machine learning algorithms for predicting cancer treatment outcomes using ADPR compositions

Obviousness Reasoning

Predictive analytics in medical treatment represent a standard approach to personalized medicine, offering a logical extension of existing therapeutic methodologies

35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857561 and the disclosed technological variations, a Person Having Ordinary Skill In The Art would find the proposed combinations of ADPR compositions with digital technologies to be obvious extensions of existing pharmaceutical and medical technological frameworks, thereby rendering potential patent claims in this domain anticipated and non-patentable under standard obviousness criteria.

Original Patent Information

Patent Number	US 11,857,561
Title	Methods for the use of 5′-adenosine diphosphate ribose (ADPR)
Assignee(s)	Invirsa, Inc.